GeoVax Labs reports Q2 net loss $4.43M, cash ~$3.1M; advances GEO‑MVA pivotal study
GeoVax Labs (GOVX) reported Q2 2026 net loss of $4.43M, or $0.97 per share, and cash of about $3.1M at June 30, 2026. Revenue was $0 after termination of a prior BARDA contract. The company said it is preparing to start a pivotal GEO-MVA immunobridging study in Q4 2026 and advancing its Gedeptin program.
How this was made
The 30-second read
Why it matters
The key trade-relevant elements are (1) the new Q2 financials including cash level and revenue cessation, and (2) operational progress toward starting a GEO-MVA pivotal immunobridging study in Q4 2026 under an expedited EMA pathway.
Market read
For GOVX, the combination of cash runway context and a specific upcoming clinical initiation window can reprice probability-weighted outcomes, even without new efficacy data.
What to watch
The article notes discontinuation of GEO-CM04S1 and reprioritization; traders may need to assess whether this reduces future optionality and increases single-program concentration risk.
Background
GeoVax is an immuno-oncology and vaccine-focused biotech; this update follows termination of a prior BARDA contract and shifts emphasis to GEO-MVA and Gedeptin.
Ticker impact
GeoVax reported Q2 2026 net loss of $4.43M, cash of about $3.1M, and progress toward initiating a GEO-MVA pivotal study in Q4 2026.
Moderate volatility risk, with upside bias if investors focus on the planned Q4 2026 GEO-MVA initiation and downside if cash burn concerns dominate.
The article provides fresh financial datapoints (loss, cash, revenue cessation) and a specific operational milestone (planned Q4 2026 initiation under an expedited EMA pathway), but it does not include trial results or funding/financing terms that would be decisive.
Market effects
Highlights ongoing funding and regulatory-pathway dependence for small biotech immunotherapy and vaccine platforms, reinforcing sector risk sensitivity to cash runway.
None explicit beyond general biotech sentiment.
EMA pathway mention may matter for European regulatory expectations, but no direct cross-border deal or approval is disclosed.
Counterpoint
Investors may discount the GEO-MVA timeline as readiness without proof of enrollment pace, while the $3.1M cash balance and BARDA revenue cessation could drive dilution risk.
Key entities
- companyGeoVax Labs, Inc.
Reported Q2 2026 net loss of $4.43M, cash of about $3.1M, and progress toward GEO-MVA pivotal study initiation in Q4 2026.
- clinical_programGEO-MVA
Pivotal immunobridging study readiness with planned Q4 2026 initiation under an expedited EMA pathway.
- clinical_programGedeptin (GDEPT)
Advancement toward combination immunotherapy strategies to enhance PD-1 checkpoint inhibitor activity.